Our clients are early-stage biotechnology, medical device, diagnostics and pharmaceutical service companies. When we begin working with a client they are frequently looking to complete proof-of-concept studies, secure intellectual property and other critical preliminary tasks. Typically we raise the first round ($1 - $5 million of capital) needed to accomplish these milestones, usually, but not always from angel investors. After key milestones have been achieved using that money, we generally follow by raising a second round of $5-20 million, usually institutional money, for development and growth.
We work closely with our clients to provide them with rigorous, credible strategic plans, raise the capital they need capital, help them to consummate strategic partnerships and, as necessary, provide them with on-going operational support. We call this sleeves-rolled-up approach to working with our clients Full-Contact Investment Banking™.
By working this way, we increase our clients' success rate raising capital and building their companies and the returns to the investors we bring into those companies. We have raised over $95 million in early stage funding for our clients (in Seed, Series A and Series B rounds) and delivered realized returns, so far, over $520 million—a realized return to date of roughly 5.5X—to the investors who provided that early stage capital, with a number of the companies still driving towards an exit that may increase that figure. Realized (cash-on-cash) internal rates of return for a hypothetical investor who participated in each round of financing offered by WG&A to date exceeds 65% annually.
We serve biotechnology, medical device and pharmaceutical service companies specializing in a variety of fields including:
- Small molecule therapeutics
- Medical devices (both 510(k) and PMA)
- Drug discovery services
- Platform Technologies for drug discovery (chemistry, biology, software, instrumentation, engineering)
- Digital Healthcare
Our clients span a range of therapeutic areas that includes oncology, dermatology, Women's health, orthopaedics, CNS, urology, wound care, cardiovascular, diabetes and ophthalmology among others.
Our clients include early stage, middle-market and publicly traded companies from all areas of life science:
- Target-based drug discovery companies (small molecule; large molecule)
- Technology platform companies
- Medical device companies
- Pharmaceutical service companies
Walter Greenblatt & Associates has worked with clients in many different therapeutic indications, across a broad range of countries, in disparate stages of development, each with radically different technologies and scientific underpinnings than the others and each founded by entrepreneurs and scientists from a vast array of backgrounds. WG&A works with clients to define and articulate strategy and then translates clients' science and technology into the language of business so investors can understand the economic value proposition. Investors in the firm's transactions come from the US, Asia, Australia, Europe and the Middle East, and include angel investors with background in medicine, biotech or pharma; family offices with a lifescience focus; lifescience-focused venture capitalists; and strategic investors/buyers including pharmaceutical, biotech, medical device and instrumentation companies.